Printer Friendly

ABBOTT FILES NEW DRUG APPLICATION FOR TREATMENT OF URINARY SYMPTOMS DUE TO ENLARGED PROSTATE

 ABBOTT FILES NEW DRUG APPLICATION FOR TREATMENT
 OF URINARY SYMPTOMS DUE TO ENLARGED PROSTATE
 ABBOTT PARK, Ill., Jan. 27 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) announced today it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the use of Hytrin (terazosin) for the treatment of the symptoms associated with benign prostatic hyperplasia (BPH). BPH is a common disease in men over the age of 50 characterized by symptoms that make urinating difficult.
 Hytrin, a selective alpha-one blocker, is currently available for the treatment of hypertension. Hypertension and BPH are common in older male patients. Hytrin is the first alpha blocker submitted for approval for BPH use in the United States.
 Hytrin is approved for BPH use in Spain and recently received scientific approval for the BPH indication in Italy.
 Abbott Laboratories is a worldwide manufacturer of health care products employing nearly 46,000 people. In 1991, the company's sales and net earnings were $6.9 billion and $1.1 billion, respect both of Abbott Laboratories/
 (ABT) CO: Abbott Laboratories ST: Illinois IN: MTC SU:


CK -- NY064 -- 3748 01/27/92 12:29 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 27, 1992
Words:191
Previous Article:1990 HIGH SCHOOL DROPOUT RATES SHOW MODERATE DECLINE
Next Article:MEDICAL PLAN COSTS TOP $3,500 PER EMPLOYEE IN 1991
Topics:


Related Articles
FIRST ADD TO MERCK ANNOUNCES PROGRAM FOR PATIENTS ON PROSCAR
PROSCAR(R) NOW AVAILABLE IN U.S. PHARMACIES; NEW DRUG TREATS COMMON PROSTATE PROBLEM IN OLDER MEN
ABBOTT, MERCK AND VA TO FUND COOPERATIVE STUDY FOR THE TREATMENT OF BPH
MERCK'S PROSCAR BEING STUDIED IN VETERAN'S AFFAIRS TREATMENT TRIAL FOR SYMPTOMATIC BENIGN PROSTATE ENLARGEMENT
MERCK AND SYNAPTIC PHARMACEUTICAL CORPORATION SIGN RESEARCH COLLABORATION AND LICENSE AGREEMENT
PROSTATE PROBLEMS: NOT JUST AN OLDER MAN'S CONCERN
FDA Clears Merck's Proscar to Reduce Need for Prostate Surgery and Risk Of Urinary Retention in Men Suffering from Enlarged Prostates
At UMDNJ-Robert Wood Johnson Medical School Survey Confirms Link Between Urinary Symptoms and Sexual Dysfunction in Men.
Eli Lilly/ICOS's Cialis Will Gain Market Share in the Treatment of Benign Prostatic Hyperplasia.
Fincar 5.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters